Evofem Biosciences Inc. (NASDAQ:EVFM) price is hovering lower on Monday, September 13, dropping -2.27% below its previous close.
A look at today’s price movement shows that the recent level at last check reads $0.83, with intraday deals fluctuating between $0.8029 and $0.85. The company’s 5Y monthly beta was ticking -0.48. Taking into account the 52-week price action we note that the stock hit a 52-week high of $5.53 and 52-week low of $0.65. The stock added 8.66% on its value in the past month.
Evofem Biosciences Inc., which has a market valuation of $132.27 million, is expected to release its quarterly earnings report Nov 08, 2021 – Nov 12, 2021. Analysts tracking EVFM have forecast the quarterly EPS to shrink by -0.31 per share this quarter, while the same analysts predict the annual EPS to hit -$1.45 for the year 2021 and up to -$0.8 for 2022. In this case, analysts estimate an annual EPS growth of 31.60% for the year and 44.80% for the next year.
On average, analysts have forecast the company’s revenue for the quarter will hit $3.96 million, with the likely lows of $3.3 million and highs of $4.61 million. The average estimate suggests sales growth for the quarter will likely rise by 130.20% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $12.25 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow 2,646.60% above that which the company brought in 2021.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give EVFM a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 3 analysts have assigned EVFM a recommendation rating as follows: 1 rate it as a Hold; 2 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Evofem Biosciences Inc. (EVFM) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Overweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that EVFM’s price is at present 2.99% off the SMA20 and -4.46% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 47.58, with weekly volatility standing at 7.09%. The indicator jumps to 8.20% when calculated based on the past 30 days. Evofem Biosciences Inc. (NASDAQ:EVFM)’s beta value is holding at -0.31, while the average true range (ATR) indicator is currently reading 0.06. Considering analysts have assigned the stock a price target range of $1.00-$5.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $3.33. Based on this estimate, we see that today’s price at last check is roughly -23.46% off the estimated low and -517.28% off the forecast high. Investors will no doubt be excited to see the share price fall to $4.00, which is the median consensus price, and at that level EVFM would be -393.83% from recent price.
An analysis of the Evofem Biosciences Inc. (NASDAQ:EVFM) stock in terms of its daily trading volume indicates that the 3-month average is 6.35 million.
Current records show that the company has 125.17M in outstanding shares. The insiders’ percentage holdings are 1.50% of outstanding shares while the percentage share held by institutions stands at 29.90%. But the -65.59% downside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.